BPC-157 Capsules

BPC-157 is a synthetic pentadecapeptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, molecular formula C62H98N16O22, molecular weight 1419.53 g/mol, and CAS number 137525-51-0. The sequence was originally described as a partial fragment corresponding to a region of a protein isolated from human gastric juice and designated 'body protection compound' by Sikiric and colleagues at the University of Zagreb, who have published the majority of the primary preclinical literature on the molecule since the early 1990s. This product is the oral capsule presentation: 500 mcg of lyophilized BPC-157 per capsule, 60 capsules per bottle, intended solely for laboratory research.

The oral format is of specific research interest because of a property reported repeatedly in the Zagreb preclinical work: BPC-157 has been described as stable in human gastric juice, with retention of activity after prolonged exposure to low pH in rodent models. Most peptides of this size are rapidly hydrolyzed by pepsin and pancreatic proteases and are therefore studied only by injection. If the stability claim reproduces in independent laboratories, the pentadecapeptide would represent an unusual case in which an oral, gut-lumen route of administration is mechanistically plausible. It is important to state directly that this stability property has been reported primarily by a single research group in rodents, and it has not been characterized in a controlled human pharmacokinetic study — no plasma exposure data in humans following oral administration have been published in the peer-reviewed literature.

What differentiates BPC-157 from other peptides marketed for tissue-repair research is the breadth of preclinical models in which activity has been reported — tendon-to-bone healing, ligament transection, muscle crush, colon anastomosis, gastric ulcer, and inflammatory bowel models — versus the near-complete absence of published human trial data. As of the current literature, no phase 2 or phase 3 randomized controlled trial of BPC-157 in humans has been published in a PubMed-indexed journal. Statements in vendor and forum sources describing 'clinical efficacy' are not supported by the primary record. Any research use of the oral capsule format should be framed against that gap: the compound is a preclinical tool with an interesting stability profile, not a clinically validated therapeutic.

The oral capsule format is chosen by investigators studying gastrointestinal endpoints — where the site of interest is the lumen or mucosa and systemic exposure is not required for the hypothesis — or as a reference arm in comparative bioavailability work against parenteral routes. The 500 mcg per capsule strength was selected to correspond, on a per-kilogram basis, to the mid-range of oral doses used in the rodent literature when scaled by conventional allometric methods; scaling is presented only as descriptive context for study design and is not a human dose recommendation.

BPC-157 does not have a single identified high-affinity receptor. The preclinical literature describes it as a pleiotropic agent whose effects have been attributed to modulation of several downstream systems. It is important to note at the outset that no crystallographic or radioligand binding study has established a primary molecular target, and the mechanisms below are inferred from tissue-level and pathway-level readouts in rodents rather than from direct receptor pharmacology.

Nitric oxide (NO) system modulation. The most consistently reported mechanistic finding is interaction with the NO pathway. In rat models of vascular occlusion, thrombosis, and mucosal injury, BPC-157 administration has been reported to counteract effects of both L-NAME (an NO synthase inhibitor) and L-arginine, suggesting a regulatory rather than agonist role on endogenous NO tone. This has been proposed as the basis for the reported endothelial and gastrointestinal mucosal effects, but the direct molecular interaction — whether with NOS isoforms, with soluble guanylate cyclase, or upstream — has not been resolved.

Growth factor and receptor expression. In a widely cited tendon-fibroblast in vitro study, BPC-157 exposure was associated with upregulation of the growth hormone receptor and enhanced fibroblast outgrowth and migration in a scratch assay. This is a cell-culture finding in isolated rat Achilles tendon fibroblasts and should not be read as evidence of tendon healing in humans. Other reports describe changes in VEGF, EGR-1, and FAK-paxillin signaling in wound and vascular models. These are individual laboratory findings, largely from the same research program, and independent replication is limited.

Central and enteric neurotransmitter systems. Effects on serotonergic and dopaminergic activity, and on the vagal 'brain-gut axis,' have been proposed in rodent behavioral and gastrointestinal models. These reports are mechanistically interesting but methodologically heterogeneous and do not translate into a defined receptor pharmacology.

Relevance to the oral route. For the capsule format specifically, the most directly applicable proposed mechanism is a local action on the gastrointestinal mucosa. If BPC-157 is stable in gastric juice as reported, then luminal exposure of the gastric and intestinal epithelium is plausible without any requirement for systemic absorption. Mucosal effects in rodent models of ethanol-induced gastric lesions, NSAID-induced enteropathy, and colitis have been reported at oral doses. Whether these effects require systemic exposure or occur through direct luminal contact remains an open question in the primary literature.

What the mechanism section cannot say. There is no established EC50 at a named receptor. There is no validated human pharmacokinetic profile after oral administration. Claims of a defined molecular target, or of quantitative potency comparisons against other tissue-repair peptides, are not supported by the peer-reviewed record and are not made here. Investigators designing studies with the oral capsule format should treat BPC-157 as a mechanistically plural compound whose local gastrointestinal effects are the best-characterized element of its profile.

The capsule format contains the same pentadecapeptide as the injectable lyophilized presentation. The properties below describe the peptide itself; capsule-format specifications (fill weight, excipients) are listed separately in the product record.

Notes on identity. The molecular formula C62H98N16O22 and monoisotopic mass are consistent with the free-acid form of the sequence above. Some early publications describe the compound as a partial sequence of a larger gastric juice protein; the 15-residue fragment is the entity referenced in essentially all subsequent pharmacological literature and is the entity supplied in this product.

Format-specific consideration. Because the capsule format is a solid oral dosage form, the peptide is not reconstituted prior to use in a research setting; handling therefore differs from the lyophilized injectable presentation. See the Handling and Storage sections for capsule-specific guidance.

Storage guidance for the capsule format differs from the lyophilized injectable presentation because the peptide is already formulated in a solid oral dosage form and is not reconstituted in aqueous buffer prior to use.

Recommended storage.

• Long-term: Store sealed bottle at 2-8 °C (standard refrigeration). This is the recommended condition for extended shelf life.
• Short-term / working stock: Room temperature (15-25 °C), protected from light and humidity, for the duration of active study use. Return to refrigeration between sessions where practical.
• Transit: Ambient temperature exposure during shipping is acceptable for the capsule format; the peptide in solid dosage form is not subject to the aqueous-phase degradation pathways that limit reconstituted peptide stability.
• Do not freeze: Repeated freeze-thaw of the capsule format offers no stability advantage and may compromise capsule shell integrity or promote condensation on removal from cold storage.

Environmental considerations.

• Humidity: Solid oral dosage forms are sensitive to moisture uptake. Keep the bottle tightly closed with any desiccant packaged with the product retained until the bottle is empty.
• Light: BPC-157 does not contain the aromatic residues most vulnerable to photodegradation (no tryptophan; no tyrosine in the canonical sequence), but standard practice is to store the sealed opaque or amber bottle away from direct light.
• Oxidation: The sequence contains no methionine or cysteine, so oxidation-driven degradation pathways that affect many peptides are less relevant here. This is one reason the compound is often described in the literature as unusually stable for an unmodified peptide.

Shelf life. Under the recommended refrigerated storage, capsule-format BPC-157 is expected to remain within specification through the labeled expiration date on the bottle. Excursions from recommended conditions do not automatically invalidate the material but should be recorded in the research log.

Disposal. Unused or expired capsules should be disposed of according to the institutional protocol for research chemicals. This is a research-use-only material and is not to be administered to humans or animals outside of an approved research protocol.